Pulmonx Co. (NASDAQ:LUNG) Shares Bought by Barclays PLC

Barclays PLC raised its holdings in Pulmonx Co. (NASDAQ:LUNG) by 1.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 94,109 shares of the company’s stock after purchasing an additional 1,679 shares during the period. Barclays PLC owned about 0.24% of Pulmonx worth $780,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in LUNG. 272 Capital LP acquired a new position in shares of Pulmonx in the 3rd quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in shares of Pulmonx in the 3rd quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Pulmonx in the 2nd quarter valued at approximately $37,000. Hsbc Holdings PLC bought a new stake in shares of Pulmonx in the 2nd quarter valued at approximately $93,000. Finally, Mackenzie Financial Corp bought a new stake in shares of Pulmonx in the 2nd quarter valued at approximately $102,000. 91.04% of the stock is owned by institutional investors and hedge funds.

Pulmonx Stock Down 1.8 %

Pulmonx stock opened at $6.72 on Thursday. The firm has a market capitalization of $265.36 million, a P/E ratio of -4.57 and a beta of 0.66. The company has a 50-day simple moving average of $6.54 and a 200-day simple moving average of $6.88. Pulmonx Co. has a one year low of $5.46 and a one year high of $14.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same quarter last year, the business earned ($0.39) earnings per share. As a group, equities analysts expect that Pulmonx Co. will post -1.53 earnings per share for the current year.

Insider Activity at Pulmonx

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,376 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.18, for a total transaction of $27,043.68. Following the completion of the transaction, the insider now owns 291,057 shares in the company, valued at approximately $1,798,732.26. The trade was a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel David Aaron Lehman sold 5,497 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.19, for a total value of $34,026.43. Following the transaction, the general counsel now owns 197,851 shares of the company’s stock, valued at $1,224,697.69. This trade represents a 2.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,873 shares of company stock worth $193,670 in the last three months. 5.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

LUNG has been the subject of a number of research analyst reports. Citigroup reiterated a “neutral” rating and issued a $7.50 price target (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Wells Fargo & Company lowered their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Finally, Stifel Nicolaus lowered their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.75.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.